24 Oct 2012 Posted in ABPI statement By Press Office
Stephen Whitehead said:
“I am pleased to welcome the Government’s consultation in to Research and Bolar Exceptions. The ABPI and its members have been engaging in this important work over the last few years with the Intellectual Property Office to encourage more companies to conduct clinical trials in the UK.
“The pharmaceutical industry researches and develops new life changing treatments every year and adds billions to the UK economy as well supporting many thousands of jobs. It is important therefore industry operates in an environment that supports its continued success and we remove barriers that could hinder on-going investment in to medical research in the UK.
“The legal framework in the UK needs to support companies so that their intellectual property rights are not infringed whilst conducting clinical trials. This will give innovators the freedom to undertake comparative studies so they can provide data on clinical effectiveness. This small but significant proposed amendment to the current Research and Bolar Exceptions will help to clarify the law in this area and support the research based pharmaceutical industry in their discovery of innovative new medicines.”
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.